---
figid: PMC6482021__jc.2018-02289f2
figlink: /pmc/articles/PMC6482021/figure/F2/
number: Figure 2
caption: Proposed mechanism of thyroid enlargement in patients with homozygous INSR
  mutation. Solid blue arrows indicate intact signaling pathways. Dashed black arrows
  indicate inhibited signaling pathways. Red Xs indicate blocked receptors and downstream
  signaling. In patients with homozygous INSR mutation the proliferative effect on
  thyroid tissue might be mediated via the direct stimulation of IGF-1R by a high
  concentration of circulating insulin and/or hyperinsulinemia-mediated upregulation
  of hybrid receptors (+). A low level of IGF-1 can upregulate the number of IGFR1
  receptors (++) and/or increase IGF-1R activity, resulting in increased insulin binding
  to IGF-1Rs with further stimulation of the MAPK pathway. MAPK-mediated proliferative
  signaling will lead to thyroid enlargement.
pmcid: PMC6482021
papertitle: Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes.
reftext: Yevgeniya S Kushchayeva, et al. J Clin Endocrinol Metab. 2019 Jun;104(6):2216-2228.
pmc_ranked_result_index: '69063'
pathway_score: 0.8708625
filename: jc.2018-02289f2.jpg
figtitle: Thyroid enlargement in patients with homozygous INSR mutation
year: '2019'
organisms: Homo sapiens
ndex: 80288b27-de97-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6482021__jc.2018-02289f2.html
  '@type': Dataset
  description: Proposed mechanism of thyroid enlargement in patients with homozygous
    INSR mutation. Solid blue arrows indicate intact signaling pathways. Dashed black
    arrows indicate inhibited signaling pathways. Red Xs indicate blocked receptors
    and downstream signaling. In patients with homozygous INSR mutation the proliferative
    effect on thyroid tissue might be mediated via the direct stimulation of IGF-1R
    by a high concentration of circulating insulin and/or hyperinsulinemia-mediated
    upregulation of hybrid receptors (+). A low level of IGF-1 can upregulate the
    number of IGFR1 receptors (++) and/or increase IGF-1R activity, resulting in increased
    insulin binding to IGF-1Rs with further stimulation of the MAPK pathway. MAPK-mediated
    proliferative signaling will lead to thyroid enlargement.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CD
  - PIK3CA
  - PIK3CB
  - AKT1
  - AKT2
  - MAPK1
  - AKT3
  - IGF1
  - INSR
  - IRS4
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - PIK3R6
  - IRS1
  - PIK3CG
  - PIK3R3
  - PDK1
  - PIK3R4
  - MAP2K2
  - MAP2K1
  - PIK3R5
  - RAF1
  - BRAF
  - IRS2
  - ARAF
  - 'NO'
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: IGF-1
  symbol: IGF1
  source: hgnc_symbol
  hgnc_symbol: IGF1
  entrez: '3479'
- word: Ä°NSR
  symbol: INSR
  source: hgnc_symbol
  hgnc_symbol: INSR
  entrez: '3643'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS4
  entrez: '8471'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals:
- word: 'NO'
  source: ''
  identifier: ''
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
